The decision by Novo Nordisk to discontinue the insulin pens will force patients to revert to syringes, complicating diabetes care for millions of people.

Novo Nordisk, which manufactures weight-loss drug Wegovy and diabetes medication Ozempic, has asked the US authorities to ...

The company, headquartered in the key swing state of Pennsylvania, has announced the creation of 330 jobs in a significant ...

A research team in China has held atoms in a state of quantum superposition for 23 minutes, suggesting tantalizing new ...

US Food and Drug Administration (FDA) regulations allow human drug compounding — in which licensed pharmacists or physicians ...

Amgen stock rebounded Wednesday, shaking off "overdone" fears that its monthly weight-loss shot, MariTide, causes excessive bone mineral density loss.Please watch the video at Investors.com - How Novo ...

In the case of popular medications like Ozempic and Wegovy, the drug manufacturer Novo Nordisk told Global News the company has mitigation plans to minimize any disruption.

The foundation, which is nonprofit, holds a majority ownership in Novo Nordisk A/S, a leading pharmaceutical company known for developing the highly successful weight-loss drugs Ozempic and Wegovy.

Hims & Hers (HIMS) has launched an online GLP-1 supply tracker where people can share information about where the popular ...

Hims & Hers Health launched a GLP-1 Supply Tracker to spotlight challenges in accessing obesity medications, addressing ...

Better known by Novo Nordisk's brand names Ozempic and Wegovy (the former of which is indicated only for type 2 diabetes), ...